Komatsu Y, Kakizaki R, Tsushima K, Sakata Y
Jpn J Antibiot. 1983 Mar;36(3):529-36.
From clinical study on micronomicin (MCR) [Sagamicin, KW-1062], the following results were obtained. MCR was administered clinically at the daily dose of 120--240 mg for 1--45 days to 23 patients. The clinical effectiveness rate of MCR was 72.7% in all cases. As side effects, exanthema, drop of blood pressure and shortness of breath were observed in 1 patient (malignant lymphoma). Elevations of S-GOT, S-GPT and BUN were encountered in some patients. However, these results might not be due to the administration of MCR, because antitumor agents on the blood transfusion had been applied to the patients suffering from underlying diseases such as leukemia or malignant tumor. Side effects, such as impairment of the 8th nerve, renal and liver function were not noted. MCR is considered to be a useful antibiotic in the treatment of various infectious diseases combined with underlying diseases, such as progressive cancer and leukemia, and the infectious diseases of the aged.
对小诺米星（MCR）[相模霉素，KW - 1062]进行的临床研究得出了以下结果。对23例患者临床使用MCR，日剂量为120 - 240毫克，用药1 - 45天。MCR在所有病例中的临床有效率为72.7%。作为副作用，1例患者（恶性淋巴瘤）出现了皮疹、血压下降和呼吸急促。部分患者出现了血清谷草转氨酶（S - GOT）、血清谷丙转氨酶（S - GPT）和血尿素氮（BUN）升高。然而，这些结果可能并非由MCR给药所致，因为对患有白血病或恶性肿瘤等基础疾病的患者使用了输血用抗肿瘤药物。未观察到第8对神经、肾和肝功能损害等副作用。MCR被认为是治疗各种伴有基础疾病（如进展期癌症和白血病）的传染病以及老年人传染病的一种有用抗生素。
